NYSE:MED - Medifast Stock Price, News, & Analysis

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast announced a quarterly dividend on Friday, June 15th. Investors of record on Friday, June 29th will be given a dividend of $0.48 per share on Wednesday, August 8th. This represents a $1.92 annualized dividend and a yield of 0.91%. The ex-dividend date is Thursday, June 28th. View Medifast's Dividend History.

Medifast Inc (NYSE:MED) issued its quarterly earnings results on Thursday, August, 2nd. The specialty retailer reported $1.16 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.98 by $0.18. The specialty retailer had revenue of $117.30 million for the quarter, compared to analysts' expectations of $101.75 million. Medifast had a return on equity of 37.25% and a net margin of 10.87%. The business's quarterly revenue was up 55.0% on a year-over-year basis. During the same quarter last year, the business earned $0.63 EPS. View Medifast's Earnings History.

Medifast is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Medifast.

Medifast issued an update on its FY18 earnings guidance on Thursday, August, 2nd. The company provided earnings per share (EPS) guidance of $4.35-4.45 for the period, compared to the Thomson Reuters consensus estimate of $3.67. The company issued revenue guidance of $460-470 million, compared to the consensus revenue estimate of $398.16 million.Medifast also updated its Q3 guidance to $1.05-1.10 EPS.

2 brokers have issued 12-month target prices for Medifast's stock. Their predictions range from $55.00 to $249.00. On average, they expect Medifast's share price to reach $152.00 in the next twelve months. This suggests that the stock has a possible downside of 28.0%. View Analyst Price Targets for Medifast.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

Some companies that are related to Medifast include MCCORMICK & Co/SH SH NV (MKC), WANT WANT CHINA/ADR (WWNTY), Greencore Group (GNCGY), Farmer Bros (FARM), China Marine Food Group (CMFO) and Jammin Java (JAMN).

Press coverage about MED stock has been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medifast earned a news impact score of 0.22 on Accern's scale. They also gave news stories about the specialty retailer an impact score of 49.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Medifast.

Medifast's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.90%), Renaissance Technologies LLC (8.31%), Dimensional Fund Advisors LP (5.79%), Acadian Asset Management LLC (3.76%), Bank of New York Mellon Corp (1.44%) and American Century Companies Inc. (1.20%). Company insiders that own Medifast stock include Charles P Connolly, Glenn W Welling, Jeffrey J Brown, Jeremy John Martin, Michael C Macdonald, Ralph Rushton and Simon TP Ridgway. View Institutional Ownership Trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, American Century Companies Inc., Martingale Asset Management L P, Castleark Management LLC, EAM Investors LLC, ClariVest Asset Management LLC, TD Asset Management Inc. and Bessemer Group Inc.. Company insiders that have sold Medifast company stock in the last year include Charles P Connolly, Glenn W Welling, Jeremy John Martin, Michael C Macdonald and Ralph Rushton. View Insider Buying and Selling for Medifast.

MED stock was bought by a variety of institutional investors in the last quarter, including Intrinsic Edge Capital Management LLC, MUFG Securities EMEA plc, BlackRock Inc., Point72 Asset Management L.P., Russell Investments Group Ltd., Osterweis Capital Management Inc., Navellier & Associates Inc and BNP Paribas Arbitrage SA. Company insiders that have bought Medifast stock in the last two years include Glenn W Welling, Jeffrey J Brown and Simon TP Ridgway. View Insider Buying and Selling for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MED stock can currently be purchased for approximately $211.10.

Medifast has a market capitalization of $2.45 billion and generates $301.56 million in revenue each year. The specialty retailer earns $27.72 million in net income (profit) each year or $2.29 on an earnings per share basis. Medifast employs 399 workers across the globe.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]